Company intelligence / Profile preview

BulBio-NCIPD

Sofia, Bulgariabulbio.com ↗
Ownership
Private
Employees
~400
Development stage
Other
01

Overview

BulBio-NCIPD is a state-owned Bulgarian biotechnology company that serves as a major global manufacturer of vaccines and immunobiological products. Headquartered in Sofia, the company is the commercial successor to the production division of the National Center of Infectious and Parasitic Diseases, with roots dating back to 1881. BulBio-NCIPD is most notably one of the world's primary suppliers of the BCG vaccine, providing millions of doses annually to international health organizations like UNICEF and the WHO. Its extensive product portfolio also includes tetanus and diphtheria toxoids, polyvalent snake antivenoms, human immunoglobulins, and a variety of diagnostic reagents. The company operates modern, GMP-certified manufacturing facilities and plays a critical role in both national and international public health immunization strategies.

Therapeutic areas
OncologyImmunologyOtherInfectious Diseases
Modalities
VaccineBiologicAntibodyProtein
Industry
Biotech
02

Drug pipeline

5 assets

Tetadif

2

4 more assets in the full pipeline.

03

Partnerships

WHOUNICEFPAHO

Beyond the preview

Go deeper on BulBio-NCIPD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BulBio-NCIPD.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call